88.42p 1.4 1.6%
Last Trade - 8:33am
| Market Cap | ÂŁ187.3m |
| Enterprise Value | ÂŁ175.1m |
| Revenue | ÂŁ581k |
| Position in Universe | 848th / 1809 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.36 | 0.50 | 0.63 | 0.68 | 0.58 | 1.50 | 0.60 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. Its Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The resulting liquid biopsy (blood test) enables the detection and investigation of mutations in the patient's cancer for personalized cancer care. The harvested CTCs have a range of applications, including diagnosis, prognosis, mutational analysis and drug selection, drug development, assessment of treatment effectiveness and remission monitoring.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | December 4, 2003 |
| Public Since | March 17, 2004 |
| No. of Shareholders: | n/a |
| No. of Employees: | 87 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 215,291,919 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | The Surrey Research Park 10 Nugent Road, GUILDFORD, GU2 7AF, United Kingdom |
| Web | https://www.angleplc.com/ |
| Phone | +44 1483 343434 |
| Contact | () |
| Auditors | RSM UK Audit LLP |
As of 8:33am, shares in Angle are trading at 88.42p, giving the company a market capitalisation of ÂŁ187.3m. This share price information is delayed by 15 minutes.
Shares in Angle are currently trading at 88.42p and the price has moved by 33.85% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Angle price has moved by 39.41% over the past year.
Of the analysts with advisory recommendations for Angle, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Angle is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Angle is scheduled to issue upcoming financial results on the following dates:
Angle does not currently pay a dividend.
Angle does not currently pay a dividend.
Angle does not currently pay a dividend.
To buy shares in Angle you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Angle are currently trading at 88.42p, giving the company a market capitalisation of ÂŁ187.3m.
Here are the trading details for Angle:
Based on an overall assessment of its quality, value and momentum, Angle is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Angle are currently priced at 88.42p. At that level they are trading at 72.41% discount to the analyst consensus target price of 320.48.
Analysts covering Angle currently have a consensus Earnings Per Share (EPS) forecast of -0.066 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Angle. Over the past six months, the relative strength of its shares against the market has been 37.53%. At the current price of 88.42p, shares in Angle are trading at 52.76% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Angle.
Angle's management team is headed by:
Here are the top five shareholders of Angle based on the size of their shareholding:
